Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxiang Suling Shuanghua Yin is a modern Chinese herbal combination developed by a team led by Professor Wang Linyuan at Beijing University of Chinese Medicine, specifically for the prevention of COVID-19 and influenza. The formula was created under the guidance of traditional Chinese medicine (TCM) epidemic prevention theory, integrating clinical experience from the COVID-19 pandemic and modern scientific research. It is designed as a preventive remedy to support immune function, clear heat, resolve dampness, and provide antiviral effects. The product uses food-grade medicinal ingredients with gentle action and employs volatile oil encapsulation technology for enhanced efficacy. It has been approved for sale in several countries including the US and Europe[2][3][5]. Mechanistically, it acts through multiple TCM principles such as aromatic dispelling of pathogens (芳香辟秽), strengthening spleen function to remove dampness (健脾利湿), supporting lung health (益肺驱痰), and boosting vital energy or "upright qi" (扶助正气)[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huoxiang Suling Shuanghua Yin.